Ayala Stock Analysis

AYLA -  USA Stock  

USD 5.39  0.13  2.36%

The big decline in price over the last few months for Ayala Pharmaceuticals could raise concerns from investors as the firm it trading at a share price of 5.39 on 10,767 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Ayala Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.85. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Ayala Pharmaceuticals partners.
Please continue to Trending Equities.

Ayala Stock Analysis 

The Ayala Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Ayala Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ayala Stock analysis module also helps to analyze the Ayala Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Ayala Stock Analysis Notes

About 52.0% of the company shares are held by company insiders. The book value of Ayala Pharmaceuticals was presently reported as 2.91. The company recorded a loss per share of 2.87. Ayala Pharmaceuticals had not issued any dividends in recent years. Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company was incorporated in 2017 and is headquartered in Rehovot, Israel. Ayala Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. For more info on Ayala Pharmaceuticals please contact the company at 972 8 373 1541 or go to https://www.ayalapharma.com.

Ayala Pharmaceuticals Quarterly Cost of Revenue


Ayala Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ayala Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ayala Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ayala Pharmaceuticals generated a negative expected return over the last 90 days
Ayala Pharmaceuticals has high historical volatility and very poor performance
Ayala Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3.36 M. Net Loss for the year was (39.6 M) with profit before overhead, payroll, taxes, and interest of 1.05 M.
Ayala Pharmaceuticals currently holds about 40.84 M in cash with (37.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.96.
Ayala Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 52.0% of the company shares are held by company insiders
Latest headline from www.nasdaq.com: Ayala Pharmaceuticals Inc Shares Fall 4.6 percent Below Previous 52-Week Low - Market Mover - Nasdaq

Ayala Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Ayala Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ayala Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Earnings Report13th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Ayala Largest EPS Surprises

Earnings surprises can significantly impact Ayala Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Ayala Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ayala Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ayala Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ayala Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
24th of January 2022
Unclassified Corporate Event
16th of September 2021
Other Events
30th of July 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of June 2021
Submission of Matters to a Vote of Security Holders

Ayala Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ayala Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ayala Pharmaceuticals backward and forwards among themselves. Ayala Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ayala Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon Shares961.6 K10.9 M
Redmile Group LlcCommon Shares667.8 K7.6 M
Ikarian Capital LlcCommon Shares538.9 K6.1 M
Sio Capital Management LlcCommon Shares318.6 K3.6 M
Boothbay Fund Management LlcCommon Shares53.8 K610 K
Bridgeway Capital Management LlcCommon Shares53 K601 K
Marshall Wace North America LpCommon Shares49.3 K559 K
Note, although Ayala Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ayala Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 81.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ayala Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ayala Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ayala Profitablity

Ayala Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Ayala Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Ayala Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ayala Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ayala Pharmaceuticals' profitability requires more research than a typical breakdown of Ayala Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.78) (0.84) 
Return on Average Equity(1.15) (1.18) 
Return on Invested Capital 27.67  24.25 
Return on Sales(7.21) (7.78) 

Management Efficiency

The entity has return on total asset (ROA) of (49.04) % which means that it has lost $49.04 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (91.76) %, meaning that it created substantial loss on money invested by shareholders. Ayala Pharmaceuticals management efficiency ratios could be used to measure how well ayala pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 29, 2022, Return on Average Assets is expected to decline to -0.84. In addition to that, Return on Average Equity is expected to decline to -1.18. Ayala Pharmaceuticals Asset Turnover is projected to slightly decrease based on the last few years of reporting. The past year's Asset Turnover was at 0.07. The current year Tangible Assets Book Value per Share is expected to grow to 4.19, whereas Total Assets are forecasted to decline to about 45.7 M.
Last ReportedProjected for 2022
Book Value per Share 4.48  4.83 
Enterprise Value over EBIT(2.70) (2.92) 
Enterprise Value over EBITDA(2.80) (3.02) 
Price to Book Value 3.29  3.27 
Tangible Assets Book Value per Share 4.18  4.19 
Enterprise Value82.6 M82.1 M
Tangible Asset Value52.7 M45.7 M

Technical Drivers

As of the 29th of January, Ayala Pharmaceuticals shows the mean deviation of 3.09, and Risk Adjusted Performance of (0.17). Ayala Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Ayala Pharmaceuticals, which can be compared to its rivals. Please confirm Ayala Pharmaceuticals jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Ayala Pharmaceuticals is priced correctly, providing market reflects its regular price of 5.39 per share. Given that Ayala Pharmaceuticals has jensen alpha of (0.83), we suggest you to validate Ayala Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Ayala Pharmaceuticals Price Movement Analysis

The output start index for this execution was seven with a total number of output elements of fifty-four. The Mid-point Price over period is an average of Ayala Pharmaceuticals highest and lowest prices attained during the given period. View also all equity analysis or get more info about midpoint price over period overlap studies indicator.

Ayala Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ayala Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ayala Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ayala Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ayala Pharmaceuticals Predictive Daily Indicators

Ayala Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ayala Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ayala Pharmaceuticals Forecast Models

Ayala Pharmaceuticals time-series forecasting models is one of many Ayala Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ayala Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Ayala Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ayala Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ayala shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Ayala Pharmaceuticals. By using and applying Ayala Stock analysis, traders can create a robust methodology for identifying Ayala entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(7.17) (7.74) 
Gross Margin 0.45  0.40 
Profit Margin(7.32) (7.89) 
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company was incorporated in 2017 and is headquartered in Rehovot, Israel. Ayala Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.

Current Ayala Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ayala analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ayala analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Ayala Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ayala analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ayala stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ayala Pharmaceuticals, talking to its executives and customers, or listening to Ayala conference calls.
Ayala Analyst Advice Details

Ayala Stock Analysis Indicators

Ayala Pharmaceuticals stock analysis indicators help investors evaluate how Ayala Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ayala Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ayala Pharmaceuticals stock analysis, traders can identify Ayala Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio7.03
Fifty Two Week Low5.40
Revenue Growth-5.00%
Shares Short Prior Month122.54k
Average Daily Volume Last 10 Day58.19k
Average Daily Volume In Three Month32.26k
Shares Percent Shares Out0.58%
Short Percent Of Float1.52%
Forward Price Earnings-2.40
Float Shares6.06M
Fifty Two Week High28.68
Enterprise Value To Ebitda-1.76
Fifty Day Average8.69
Two Hundred Day Average10.46
Enterprise Value To Revenue20.22
Please continue to Trending Equities. Note that the Ayala Pharmaceuticals information on this page should be used as a complementary analysis to other Ayala Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Ayala Stock analysis

When running Ayala Pharmaceuticals price analysis, check to measure Ayala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ayala Pharmaceuticals is operating at the current time. Most of Ayala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ayala Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ayala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ayala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Transaction History
View history of all your transactions and understand their impact on performance
Is Ayala Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ayala Pharmaceuticals. If investors know Ayala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ayala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ayala Pharmaceuticals is measured differently than its book value, which is the value of Ayala that is recorded on the company's balance sheet. Investors also form their own opinion of Ayala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ayala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ayala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ayala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ayala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Ayala Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ayala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.